Which has the lower trailing P/E, ASND or CORT?

ASND has the lower trailing P/E: ASND trades at 17.33 and CORT at 290.55. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ASND or CORT?

Over the past five years, ASND grew revenue faster — ASND at a 189.92% CAGR versus CORT at 19.35%.

Is ASND or CORT more profitable?

ASND runs the higher net margin — ASND at 71.08% versus CORT at 6.61%.

How have ASND and CORT total returns compared?

Over the past 10 years, ASND delivered 27.41% and CORT delivered 33.70% annualized total return. Past performance doesn't predict future results.

Ascendis Pharma A/S (ASND) vs Corcept Therapeutics Incorporated (CORT)

A side-by-side comparison of Ascendis Pharma A/S and Corcept Therapeutics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ASND

Ascendis Pharma A/S

$14.16B

$228.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

CORT

Corcept Therapeutics Incorporated

$13.19B

$122.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ASND vs CORT

growth of $100 · dividends reinvested · last 10y

ASND +1027.2% (+27.4%/yr)CORT +1837.0% (+34.5%/yr)CORT compounded faster over this window

ASND CORT

ASND vs CORT: by the numbers

•ASND is the larger company ($14.16B vs $13.19B market cap).
•ASND trades at the lower trailing earnings multiple (17.33 vs 290.55 P/E), one valuation lens rather than an overall verdict.
•ASND converts more revenue to profit (71.08% vs 6.61% net margin).
•ASND grew revenue faster over the past five years (189.92% vs 19.35% CAGR).

Metrics side by side

Valuation

Metric	ASND	CORT
P/E ratio	17.33	290.55
P/S ratio	11.59	15.88
P/B ratio	8.64	18.69
EV / EBITDA	93.79	1483.24
FCF yield	2.73%	0.81%

Profitability

Metric	ASND	CORT
Gross margin	90.18%	98.30%
Operating margin	-18.92%	0.77%
Net margin	71.08%	6.61%
ROE	52.97%	7.78%
ROIC	5.85%	0.87%

Growth (annualized)

Metric	ASND	CORT
Revenue CAGR (5Y)	189.92%	19.35%
EPS CAGR (5Y)	N/A	0.64%
FCF CAGR (5Y)	N/A	-4.40%
Total return CAGR (5Y)	7.40%	43.90%

Frequently asked

Which has the lower trailing P/E, ASND or CORT?: ASND has the lower trailing P/E: ASND trades at 17.33 and CORT at 290.55. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ASND or CORT?: Over the past five years, ASND grew revenue faster — ASND at a 189.92% CAGR versus CORT at 19.35%.
Is ASND or CORT more profitable?: ASND runs the higher net margin — ASND at 71.08% versus CORT at 6.61%.
How have ASND and CORT total returns compared?: Over the past 10 years, ASND delivered 27.41% and CORT delivered 33.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ASND analysis Full CORT analysis Interactive comparison tool

Dig into the metrics

Ascendis Pharma A/S P/E ratio Corcept Therapeutics P/E ratio Ascendis Pharma A/S ROE Corcept Therapeutics ROE Ascendis Pharma A/S operating margin Corcept Therapeutics operating margin Ascendis Pharma A/S revenue growth Corcept Therapeutics revenue growth Ascendis Pharma A/S free cash flow Corcept Therapeutics free cash flow

Ascendis Pharma A/S & Corcept Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.